Umer Raffat
Stock Analyst at Evercore ISI Group
(1.45)
# 3,509
Out of 5,163 analysts
19
Total ratings
56.25%
Success rate
-3.92%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $39.89 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $13.99 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $0.47 | - | 1 | Feb 28, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $27.76 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $26.33 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $28.57 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $10.37 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $26.19 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $18.75 | - | 1 | Nov 2, 2022 | |
| OGN Organon & Co. | Initiates: Outperform | n/a | $6.35 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.19 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $960 | $13.48 | +7,021.66% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $366.21 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $7.22 | +564.82% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $178.55 | - | 1 | Feb 23, 2017 |
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $39.89
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $13.99
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.47
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $27.76
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $26.33
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $28.57
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $10.37
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $26.19
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $18.75
Upside: -
Organon & Co.
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.35
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.19
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $960
Current: $13.48
Upside: +7,021.66%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $366.21
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $7.22
Upside: +564.82%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $178.55
Upside: -